SEC Comment Letter for Moleculin Biotech, Inc. (MBRX) (CIK 0001659617) (MBRX) — Jul 19, 2018
Moleculin Biotech, Inc. (MBRX) (CIK 0001659617)
Date: July 19, 2018 · CIK: 0001659617 · Accession: 0000000000-18-022235
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226146
Letter
July 19, 2018 Walter Klemp Chief Executive Officer Moleculin Biotech, Inc. 2575 West Bellfort, Suite 333 Houston, TX 77054 Re:Moleculin Biotech, Inc. Registration Statement on Form S-1 Filed July 12, 2018 File No. 333-226146 Dear Mr. Klemp: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Cavas S. Pavri, Esq.
Show Raw Text
July 19, 2018
Walter Klemp
Chief Executive Officer
Moleculin Biotech, Inc.
2575 West Bellfort, Suite 333
Houston, TX 77054
Re:Moleculin Biotech, Inc.
Registration Statement on Form S-1
Filed July 12, 2018
File No. 333-226146
Dear Mr. Klemp:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Cavas S. Pavri, Esq.